Last Updated : May 3, 2024
Details
Generic Name:
Brentuximab vedotin
Project Status:
Active
Therapeutic Area:
Hodgkin lymphoma
Manufacturer:
Seagen Canada Inc.
Brand Name:
Adcetris
Project Line:
Reimbursement Review
Project Number:
PC0371-000
Tumour Type:
Lymphoma
NOC Status at Filing:
N/A
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Brentuximab vedotin in combination with doxorubicin, vincristine, etoposide, prednisone and cyclophosphamide in previously untreated high-risk HL in the pediatric population. Brentuximab vedotin in combination with doxorubicin, vinblastine, and dacarbazine for the treatment of previously untreated patients with advanced stage Hodgkins Lymphoma.
Submission Type:
Initial
Fee Schedule:
N/A
Indications:
Brentuximab vedotin in combination with doxorubicin, vincristine, etoposide, prednisone and cyclophosphamide in previously untreated high-risk HL in the pediatric population. Brentuximab vedotin in combination with doxorubicin, vinblastine, and dacarbazine for the treatment of previously untreated patients with advanced stage Hodgkins Lymphoma
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | March 08, 2023 |
|---|---|
| Call for patient/clinician input closed | May 02, 2023 |
| Clarification: - Patient input submission received from Lymphoma Canada | |
| Submission received | April 18, 2024 |
| Submission accepted | May 03, 2024 |
| Review initiated | May 06, 2024 |
| CADTH review report(s) and responses to comments provided to sponsor | June 27, 2024 |
| Expert committee meeting (initial) | July 10, 2024 |
| Draft recommendation issued to sponsor | July 22, 2024 To July 24, 2024 |
| Draft recommendation posted for stakeholder feedback | August 01, 2024 |
| End of feedback period | August 16, 2024 |
Last Updated : May 3, 2024